Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
do not massage
[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
Details of the National Institutes of Health-funded study were published this week in a Nature paper titled A brain reward circuit inhibited by next-generation weight-loss drugs in mice. In it, the team reported that they investigated the small-molecule GLP-1s including Eli Lillys recently approved drug orforglipron, also known by the brand name Foundayo, as well as danuglipron, an oral GLP-1 that was being developed by Pfizer until the company decided to discontinue its development in 2025
Central role of microglia in sepsis-associated encephalopathy: From mechanism to therapy
